Live Biotherapeutics Drug Discovery Services for Gastrointestinal Disorders

Next-generation probiotics (NGPs) have been widely investigated as a treatment modality for gastrointestinal disorders. With extensive expertise in the human probiotic field, Creative Biolabs is committed to deepening our understanding of the role of microbiota in human health aided by our next-generation sequencing and analytic tools, experimental technologies, and animal models. We have explored a live biotherapeutics discovery platform for NGP development, pre-clinical studies, and cGMP manufacturing to address different demands for pre-clinical, clinical, and commercial applications.

NGPs for Gastrointestinal Disorders Management

The human microbiota is a very complex ecologic system that is necessary for health but also has the potential to contribute to the development of diseases. To alter the intestinal microflora, there are four general methods: administration of antibiotics, administration of antibiotics, prebiotics (dietary components that promote the growth and metabolic activity of beneficial bacteria), probiotics (live, beneficial bacteria), or fecal microbial transplant (FMT). Lactic acid bacteria (LAB) probiotics have been shown to synthesize many healthy metabolites with pharmaceutical properties. The probiotic L. gasseri acts by maintaining intestinal barrier integrity. Therefore, the protective effect of this probiotic can be exploited as a biological therapy to combat the progression of inflammatory intestinal diseases. Perturbations of bacterial microflora in the intestinal epithelial barrier are associated with several gastrointestinal (GI) conditions, the best studied of which are the following:

Mechanisms of Action

There is a complex relationship between GI diseases, health, the immune system, and alterations in the microbiota, therefore, the mechanisms of action of NGPs are comparatively complex and likely differ by bacteria species.

• Block the adhesion of pathogenic bacteria to the intestinal epithelium; produce inhibitory agents;
• Enhance the intestinal immune response;
• Maintain normal levels of short-chain fatty acids;
• Modulate immune system function, such as suppression of intestinal pro-inflammatory cytokines;
• Repair intestinal permeability;
• Suppress the growth of pathogenic bacteria by directly binding to gram-negative bacteria;
• Upregulate intestinal electrolyte absorption.

NGPs for Gastrointestinal Disorders

Strains of bacteria that have been widely genetically engineered to prevent and treat GI diseases (given alone or in combination) are under constant development. There is a range of NGP strains has been investigated, mainly including the following species:

What We Can Do?

With industry-leading expertise and state-of-the-art single-use equipment, Creative Biolabs provides flexible solutions to choose from, either stand-alone service or integrated projects both welcome to meet every specific demand. We aspire to become a leading, fully integrated biopharmaceutical company focused on the discovery and analysis of next-generation probiotics.

• One-stop NGP drug discovery service, from strain identification and validation to analysis and qualification.
• Stand-alone service: every step of the NGP discovery pipeline is available, such as strain isolation, immune- and cell analytics, whole metagenomic profiling, safety test, cell bank creation and storage, fermentation, lyophilization, etc.

Supplementation of the gastrointestinal microbiota with appropriate NGPs is now widely used as an alternative therapeutic approach for GI disorders. Based on our expertise in microbiota and microbiome science, Creative Biolabs provides comprehensive services for the development of NGPs from carefully selected strains. Separate services or integrated end-to-end solutions are all welcomed. If you are interested in our services, please feel free to contact us.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.